A Study of Duvelisib in Combination With Pembrolizumab in Head and Neck Cancer

Head and Neck Squamous Cell Carcinoma Clinical Trial

Official title:

A Phase 1b/2 Study of Duvelisib in Combination With Pembrolizumab in Subjects With Recurrent or Metastatic Head and Neck Squamous Cell Cancer

Clinical Trial Details — Status: Terminated

Administrative data

• NCT number: NCT04193293
• Other study ID #: VS-0145-130
• Status: Terminated
• Phase: Phase 1/Phase 2
• Start date: June 1, 2020
• Est. completion date: December 10, 2020

Study information

• Verified date: September 2023
• Source: SecuraBio
• Contact: n/a
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

This study was designed to assess the safety and preliminary efficacy of duvelisib in combination with pembrolizumab in participants with recurrent or metastatic (R/M) head and neck squamous cell carcinoma (HNSCC).

Description:

This was a non-randomized, open-label Phase 1b/2 study designed to evaluate safety, tolerability, and preliminary efficacy of duvelisib in combination with pembrolizumab in participants with R/M HNSCC who were eligible for pembrolizumab monotherapy based on the current pembrolizumab prescribing information.

Recruitment information / eligibility

• Status: Terminated
• Enrollment: 2
• Est. completion date: December 10, 2020
• Est. primary completion date: December 10, 2020
• Accepts healthy volunteers: No
• Gender: All
• Age group: 18 Years and older

Eligibility

Inclusion Criteria

• Eastern Cooperative Oncology Group performance status = 1

• Histologically or cytologically confirmed diagnosis of recurrent or metastatic head and neck squamous cell carcinoma of the oral cavity, oropharynx, hypopharynx, or larynx that was considered incurable by local therapies

• Eligible for pembrolizumab monotherapy based on the current prescribing information for pembrolizumab (Keytruda 2019)

• Must have had 0 to 2 prior therapies for R/M HNSCC

• At least 1 measurable lesion (which has not been previously irradiated) according to Response Evaluation Criteria in Solid Tumors version 1.1

• For stage 1 only: Must have had at least 1 other lesion that could be biopsied and willing to undergo a pretreatment and on-treatment biopsy of the available tumor lesion

• For stage 1 only: Must have been willing to undergo a pretreatment and on-treatment biopsy of the available tumor lesion

• Adequate organ function defined by the following laboratory parameters:

• Absolute neutrophil count = 1.5 × 10^9/liter (L)

• Platelet count = 100 × 10^9/L

• Hemoglobin level = 9.0 grams/deciliter (dL)

• A serum creatinine level < 1.5 milligrams/dL, or

• Estimated creatinine clearance value = 60 milliliters/minute (as determined by the Cockcroft-Gault method) for participants with creatinine levels > 1.5 × institutional upper limit of normal (ULN)

• Total bilirubin level = 1.5 × ULN (exception: participants with Gilbert's Syndrome may have a bilirubin level > 1.5 × ULN)

• Aspartate aminotransaminase/serum glutamic-oxaloacetic transaminase and alanine aminotransferase/serum pyruvic transaminase levels = 2.5 × ULN or = 5 × ULN in participants with liver metastases

• International normalized ratio or prothrombin time (PT) and activated partial thromboplastin time (aPTT) = 1.5 × ULN, unless participant was receiving anticoagulant therapy in which case PT or aPTT must have been within therapeutic range of intended use of anticoagulants

Exclusion Criteria

• Previously treated with 3 or more systemic regimens given for recurrent and/or metastatic disease

• Received anticancer treatment, major surgery, or any investigational drug within 30 days or 5 half-lives, whichever is shorter, before the start of study intervention

• Received radiation therapy within 14 days before the start of study intervention, including, in addition (if necessary), the timeframe for resolution of any actual or anticipated toxicities from such radiation; Palliative radiation is allowed if > 7 days and any toxicity is = Grade 1

• Previous treatment with a PI3K, PD-1 or programmed cell death ligand 1 inhibitor

• Have received organ or allogenic bone marrow or peripheral blood stem cell transplant

• History of drug-induced colitis or drug-induced pneumonitis; history or concurrent condition of interstitial lung disease of any severity and/or severely impaired lung function; tuberculosis treatment within 2 years prior to the start of study intervention; chronic liver disease or veno-occlusive disease/sinusoidal obstruction syndrome

• Active cytomegalovirus or Epstein-Barr virus infection; history of or known human immunodeficiency virus infection

• Ongoing treatment with chronic immunosuppressants or systemic steroids or treatment for systemic bacterial, fungal, or viral infection

• Unable to receive prophylactic treatment for pneumocystis, herpes simplex virus (HSV), or herpes zoster (VZV) at screening

• Concurrent administration of medications or foods that are strong inhibitors or inducers of cytochrome P450 3A. No prior use within 2 weeks before the start of study intervention Received a live or live attenuated vaccine within 6 weeks of first dose of duvelisib

• Unable to receive prophylactic treatment for pneumocystis, HSV, or VZV at screening

• Any active gastrointestinal dysfunction interfering with the participant's ability to be administered oral medications

• Known active central nervous system metastases and/or carcinomatous meningitis

• QT interval > 500 milliseconds (except for participants with a right or left bundle branch block)

• New York Heart Association Class III or IV congestive heart failure

Related Conditions & MeSH terms

• Carcinoma, Squamous Cell
• Head and Neck Squamous Cell Carcinoma
• Squamous Cell Carcinoma of Head and Neck

Intervention

Drug:
• Duvelisib
Phosphoinositide 3-kinase (PI3K) Inhibitor

Biological:
• Pembrolizumab
Immunotherapy (programmed cell death protein 1 [PD-1] inhibitor)

Locations

Country	Name	City	State
United States	UPMC Hillman Cancer Center	Pittsburgh	Pennsylvania

Sponsors (1)

Lead Sponsor	Collaborator
SecuraBio

Country where clinical trial is conducted

United States, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Stage 1: Number of Participants With Dose-limiting Toxicities		4 weeks or 28 days
Primary	Stage 1: Number of Participants With Treatment-emergent Adverse Events (TEAEs)	Number of participants with TEAEs as assessed by the Common Terminology Criteria for Adverse Events version 5 (CTCAE v5) as a measure of safety and tolerability of duvelisib in combination with pembrolizumab.	6 months
Primary	Stage 1 and 2: Overall Response Rate (ORR)	Proportion of participants achieving complete response (CR) or partial response (PR) according to Response Evaluation Criteria in Solid Tumors version 1.1 (RECIST v 1.1).	Up to 2 years
Secondary	Stage 1: ORR	Proportion of participants achieving complete CR or PR according to RECIST v 1.1.	Until documented progressive disease (PD), unacceptable toxicity, discontinuation criteria are met, withdrawal, or death (up to 2 years)
Secondary	Stage 1 and 2: Duration of Response (DOR)	Time from response = PR to documented disease progression according to RECIST v 1.1.	From first response until documented PD (up to 2 years)
Secondary	Stage 1 and 2: Progression-free Survival (PFS)	Time from start of treatment to documented disease progression according to RECIST v 1.1, or death due to any cause.	From start of treatment until documented PD or death (up to 2.5 years)
Secondary	Stage 1 and 2: Overall Survival	Time from start of treatment to death.	From start of treatment until death (up to 2.5 years)
Secondary	Stage 1 and 2: Maximum Observed Concentration [Cmax]	Pharmacokinetics (PK) parameters for duvelisib (and metabolite IPI-656) determined using bioanalytical data and Population PK (POPPK) modeling.	Up to 5 cycles (46 weeks)
Secondary	Stage 1 and 2: Area Under the Curve [AUC]	PK parameters for duvelisib (and metabolite IPI-656) determined using bioanalytical data and POPPK modeling.	Up to 5 cycles (46 weeks)
Secondary	Stage 1 and 2: Number of Participants With TEAEs	Number of participants with TEAEs as assessed by CTCAE v5.0.	24 months